Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

The Glioblastoma Multiforme Market is set to soar high with a CAGR of 8.25% in the 7MM for the Study Period 2017-30, estimates DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

09 Nov, 2020, 14:30 GMT

Share this article

Share toX

Share this article

Share toX

LAS VEGAS, Nov. 9, 2020 /PRNewswire/ -- Emerging novel therapeutic agents that have the potential to cross the Blood-Brain-Barrier (BBB) in the vast Glioblastoma multiforme (GBM) pipeline in different clinical stages of development is one of the significant reasons behind the soaring Glioblastoma market size growth. An increase in GBM incidence is also providing the much-needed boost to the GBM market size growth along with an increase in the scale of R&D, advances in neuroscience, drug-delivery, and diagnostics. 

DelveInsight's Glioblastoma Multiforme Market report delivers an in-depth understanding of the Glioblastoma multiforme, historical and forecasted epidemiology trends as well as the Glioblastoma multiforme market landscape, and forecast in the 7MM (the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan) for the study period of 2017-2030.

Glioblastoma multiforme market report highlights: 

  • The present Glioblastoma multiforme treatment market offers Avastin (Genentech) as the first clinically available angiogenesis inhibitor in the United States. In September 2014, Genentech reclassified the drug under "Specialty drugs," only to be available through speciality pharmacies (under FDA's Risk Evaluation and Mitigation Strategy (REMS) program).
  • The USA is anticipated to occupy the maximum share of the GBM drugs market by 2030.
  • Late-stage therapies, including Rindopepimut (Celldex Therapeutics) and ABT-414 (AbbVie), if approved, are expected to add to the GBM market revenue. 
  • The Glioblastoma multiforme pipeline constitutes gene therapy such as Ofranergene obadenovec (VB-111) (VBL Therapeutics), followed by four vaccine/immunotherapy candidates such as VBI-1901, AV-GBM-1 and ITI-1000 (pp65 DC Vaccine), Tasadenoturev (DNX-2401) by VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, respectively which will add to the GBM market size growth. 

To know how the trends will be impacting the market, download sample@ Glioblastoma multiforme treatment market 

Glioblastoma multiforme is an aggressive, malignant, and lethal tumor of the brain with a global incidence of around 2-3 per 100,000 people. GBMs account for about 17% of all the tumors of the brain (primary and metastatic). Shreds of evidence exist that link numerous genetic abrasions with GBM. Three significant signaling pathways that are found to be affected as a major cause reason behind GBM are receptor tyrosine kinase/RAS/PI3K found in almost 88% of the total GBMs cases, P53 pathway in 87% of GBMs, and RB signaling pathway in approximately 78% of GBMs. 

DelveInsight estimates the total Glioblastoma multiforme incident population in the 7MM was estimated to be around 2900 in 2017, which is anticipated to further increase by 2020 to 29,440. GBM epidemiological analysis reveals a higher incidence of males as compared to females. 

Visit, Glioblastoma multiforme market insights report, to know more about the report offerings

The Glioblastoma multiforme market report proffers in detail epidemiological scenario, 3-year historical and 11-year forecast, for the study period 2017-30 in the 7MM segmented into: 

  • Total Diagnosed Glioblastoma Multiforme Incident Population 
  • Gender-specific Diagnosed Glioblastoma Multiforme Incidence 
  • Type-specific Diagnosed Glioblastoma Multiforme Incidence
  • Age-specific Diagnosed Glioblastoma Multiforme Incidence 
  • Diagnosed Incident Population-based on Primary Site of Glioblastoma Multiforme Tumour 
  • Diagnosed Incident Population-based on Histologic Classification of Glioblastoma Multiforme Tumor 

Glioblastoma multiforme Drugs Market

At present, the treatment landscape of Glioblastoma multiforme comprises a combination of surgery, chemotherapy, radiation, or stereotactic radiosurgery. Surgery alone is never possible, owing to the infiltration of the tumor cells in the whole brain. Thus, the first-line treatment of GBM involves drug therapy following surgery, which includes Temozolomide + Radiation Therapy and Temozolomide monotherapy. For the second-line treatment of Glioblastoma multiforme, Bevacizumab monotherapy, Bevacizumab combination therapy, Temozolomide (both as combination and monotherapy), and other systemic therapies (concomitant and adjuvant) are available in the Glioblastoma multiforme market. 

Glioblastoma multiforme Marketed Therapies

  • Surgery (Craniotomy, Awake craniotomy, Debulking surgery, Skull base surgery, Visualase, and Kyphoplasty)
  • Chemotherapy (Temozolomide, Bevacizumab, Lomustine)
  • Radiation Therapy (X-rays, Gamma rays or Photons)
  • Others (Targeted Therapies, Immunotherapies and Tumour-Treating Fields (TTF))

The present treatment is palliative in nature, and despite several advances in surgical resection, the therapies have failed to increase the survival rate. The cost associated with the surgeries also poses a considerable burden on the patients and does not guarantee 100% tumor removal. Inadequate knowledge of brain tumors and common symptoms such as headaches, nausea, blurry vision also delay in diagnosis. Further, the available therapies fail to cross Blood-Brain-Barrier (BBB), which is one of the significant reasons behind the poor prognosis. GBMs are known for their Intratumor heterogeneity, which leads to drug-resistance, resulting in treatment failure. 

However, several companies are working in the Glioblastoma multiforme market landscape to address the prevailing unmet needs in the treatment market. The Glioblastoma multiforme pipeline constitutes novel and diverse therapeutic agents to be launched in the coming decade. Gene therapies, targeted therapies, therapeutic vaccines, multi-kinase inhibitors PD-1/PD-L1 inhibitor, monoclonal antibodies, a selective antagonist of dopamine receptor D2 (DRD2), and ClpP agonists including many such more candidates are under different phases of clinical trials. 

Glioblastoma multiforme drugs market: Key Companies and Pipeline Therapies

  • VBL Therapeutics: VB-111
  • Diffusion Pharmaceuticals: Trans Sodium Crocetinate
  • Kazia Therapeutics: Paxalisib
  • Aivita Biomedical: AV-GBM-1
  • Medicenna: MDNA55
  • VBI Vaccines: VBI-1901
  • Karyopharm Therapeutics: Selinexor (KPT-330)
  • Oncoceutics: ONC201
  • DNAtrix: Tasadenoturev (DNX-2401)
  • MedImmune: Durvalumab
  • Bayer: Regorafenib

Know which emerging therapy is going to be a market leader in the upcoming year by clicking@ Glioblastoma multiforme market forecast

Several therapies in the trials have produced promising clinical outcomes improving the overall survival rate. However, in the light of promising clinical trial results, the past failures of the therapies at late-stage trials cannot be overlooked. The fate of therapies such as Rindopepimut (Celldex Therapeutics) and ABT-414 (AbbVie) remains unpredictable until they reach the stage of sealing in a recommendation from the regulatory bodies. 

In a nutshell, the expected launch of novel therapeutic agents in the GBM pipeline is anticipated to fuel the market share growth in the next decade. DelveInsight estimates that the Glioblastoma multiforme market size in the 7MM is expected to witness dramatic growth in the forecast period 2020-30. The USA is anticipated to occupy the maximum share of the GBM drugs market. The emergence of innovative drug delivery approaches, rising incidence, therapies that have the potential to cross BBB, an increase in the R&D in the brain tumors, and raising awareness about the brain tumors shall expedite the GBM market size growth further. 

Scope of the Report

  • Geography Covered: 7MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.
  • Study Period: 3-year historical and 11-year forecasted analysis (2017-2030).
  • Markets Segmentation: By Geographies, By Therapies (Forecasted + Historical).
  • Companies Covered: Bayer, Diffusion Pharmaceuticals, VBL Therapeutics, AstraZeneca, DNAtrix, DelMar Pharmaceuticals, Oncoceutics, KaryoPharma, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Immunomic Therapeutics, Inovio Pharmaceuticals, among others.
  • Analysis: Comparative and conjoint analysis of emerging therapies, Attribute analysis.
  • Case Studies
  • KOL's Views
  • Analyst's View

Request for a Webex demo @ Glioblastoma multiforme Report

Table of Contents 

1

Key Insights

2

Glioblastoma Multiforme Market Overview at a Glance

3

Executive Summary of Glioblastoma Multiforme

4

Glioblastoma Multiforme Market Overview at a Glance

5

Disease Background and Overview: Glioblastoma Multiforme

6

Glioblastoma Multiforme Epidemiology and Patient Population

7

Country Wise-Epidemiology of Glioblastoma Multiforme

8

Glioblastoma Multiforme Treatment

9

Glioblastoma Multiforme Treatment Algorithm 

10

The American Society of Clinical Oncology (ASCO) Endorsed American Society for Radiation Oncology (ASTRO) Guideline on Radiation Therapy for Glioblastoma

11

The National Comprehensive Cancer Network (NCCN) Guidelines for Glioblastoma

12

Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions

13

SEOM (Medical Oncology Spanish Society) Clinical Guidelines for Diagnosis and Treatment of Glioblastoma

14

Recognized Establishments

15

Glioblastoma Multiforme Unmet Needs

16

Glioblastoma Multiforme Marketed Therapies

17

Glioblastoma Multiforme Emerging Therapies

18

Glioblastoma Multiforme 7 Major Market Analysis

19

Glioblastoma Multiforme Market Access and Reimbursement

20

Glioblastoma Multiforme Case Reports

21

KOL Views

22

Glioblastoma Multiforme Market Drivers

23

Glioblastoma Multiforme Market Barriers

24

SWOT Analysis

25

Appendix

26

DelveInsight Capabilities

27

Disclaimer

28

About DelveInsight

Related Reports 

Recurrent Glioblastoma Market Insight, Epidemiology and Market Forecast -2030

DelveInsight's "Recurrent Glioblastoma - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Recurrent Glioblastoma, historical and forecasted epidemiology as well as the Recurrent Glioblastoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us:

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg  

Modal title

Also from this source

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

DelveInsight's GPRC5D-directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive...

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

DelveInsight's Sleep Apnea Market Insights report includes a comprehensive understanding of current treatment practices, sleep apnea emerging drugs,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.